MM-310

N/A

Report date: 2022/11/25 18:08:15

Base Information

Drug NameMM-310

Drug Alias NameMM-310

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionEphrin receptor modulatorsEphrin type-A receptor 2 antagonists

TargetsEphrin type-A receptor 2Ephrin receptor

Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsEndometrial Neoplasms +[12]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMerrimack Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMerrimack Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursProstatic NeoplasmsEndometrial Neoplasms +[12]

Other Information

ATC CodeN/A